Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of ($1.09), $0.11 worse than the analyst estimate of ($0.98). Revenue for the quarter came in at $20.1 million versus the consensus estimate of $24.38 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.